MarketCap
Facebook
X
TelegramAnnual report 2022
added 04-28-2023
Jounce Therapeutics Depreciation & Amortization 2011-2026 | JNCE
Annual Depreciation & Amortization Jounce Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.09 M | 2.83 M | 3.4 M | 3.85 M | 3.83 M | 4.42 M | 1.94 M | 1.47 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.42 M | 1.47 M | 2.98 M |
Quarterly Depreciation & Amortization Jounce Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.64 M | - | 590 K | - | 2.18 M | - | 785 K | - | 2.6 M | 1.8 M | 938 K | - | 2.91 M | 1.92 M | 960 K | - | 2.87 M | 1.91 M | 947 K | - | 3.5 M | 2.59 M | 966 K | - | 1.4 M | 912 K | 447 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.5 M | 447 K | 1.68 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M |  USA |
 |
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | USA |
 |
Aptorum Group Limited
APM
|
1.13 M | $ 0.88 | - | $ 6.47 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.67 | - | $ 3.76 B | USA |
 |
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | USA |
 |
Galectin Therapeutics
GALT
|
1 K | $ 2.32 | - | $ 148 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
487 K | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | USA |
 |
Innoviva
INVA
|
26.3 M | $ 23.69 | - | $ 1.6 B | USA |
 |
Aquestive Therapeutics
AQST
|
548 K | $ 4.09 | - | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
700 K | $ 23.29 | - | $ 2.96 B | USA |
 |
Jaguar Health
JAGX
|
1.91 M | $ 0.24 | - | $ 560 K | USA |
 |
KalVista Pharmaceuticals
KALV
|
969 K | $ 19.24 | - | $ 1.04 B |  Britain |
 |
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.48 | - | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 2.91 | - | $ 4.79 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |